APR Begins Supplying Medicube Skin Boosters in Latin America, Expanding Global Reach

Pre-launch event to be held in Chile... Official local launch scheduled for November
Expanding Latin American supply network backed by Pyeongtaek production facility and regulatory approvals

Global beauty company APR is expanding its global business by supplying skin boosters from its flagship brand Medicube to Latin American markets. The company plans to establish local distribution networks based on its production capabilities and product-specific regulatory approvals, and to step up its efforts to enter overseas markets.

APR announced on October 15 that it recently began supplying Medicube skin boosters overseas, primarily to Latin America. It is currently supplying some of its products to the region and plans to invite around 300 local clinic representatives, medical professionals, and influencers to Santiago, Chile, on October 20 for an official distributor certificate presentation ceremony and pre-launch event. The official launch in Chile is scheduled for November 2026.

The products being supplied are AGE-R and AGE-R PLUS G, two products developed using PN (polynucleotide), a material derived from salmon DNA. AGE-R is an adhesive transparent wound dressing applied to the skin, while AGE-R PLUS G is a tissue-repair biomaterial injected directly under the skin. APR plans to meet local demand with product lines tailored to each product's classification and method of use.

APR has also worked to build production infrastructure to expand its skin booster business. In the second half of 2024, it announced plans to enter the business and introduced APR Factory's Third Campus, located in Pyeongtaek, Gyeonggi Province. The Third Campus, a specialized production facility for PN materials, began full-scale production in July 2026 after obtaining the relevant environmental permits and establishing manufacturing and quality management systems. The company is also strengthening its business capabilities by recruiting specialists in medical device research and development, regulatory approvals and compliance, and nonclinical and efficacy testing.

Product-specific regulatory approvals are also supporting the expansion of overseas supply. APR's AGE-R and AGE-R PLUS G have received, respectively, certification as a Class II medical device and approval as a Class IV medical device for export from the Ministry of Food and Drug Safety. APR supplied some products overseas in the first half of 2026, and plans to gradually expand its distribution to major markets such as Japan and the Middle East, beginning with the launch of distribution in Chile.

An APR representative said, "Chile is a market with relatively high per capita income and sophisticated consumer trends, even by Latin American standards, and we expect it to serve as a strategic foothold for entering the region's premium market. Starting with Chile, we plan to expand supply to key neighboring markets and gradually broaden our business in global markets by strengthening our production capabilities and product-specific regulatory approvals."

This content was produced with the assistance of AI translation services.